DOJ directive signals renewed enforcement of pharma anti-kickback law

The Justice Department issued a directive emphasizing prosecution of violations under the federal anti-kickback statute, signaling a shift toward more aggressive enforcement against drugmakers. The directive is part of a broader white-collar fraud initiative, but specific targets or cases are not named. This raises legal and financial risk for pharmaceutical companies, potentially affecting compliance costs and settlement exposure.